Showing 2671-2680 of 10620 results for "".
Targeting RET Alterations: Selpercatinib's Role in Pediatric Thyroid Cancer
https://reachmd.com/programs/project-oncology/targeting-ret-alterations-selpercatinibs-role-in-pediatric-thyroid-cancer/24476/Learn about the clinical trial data that led to the FDA approval of selpercatinib for pediatric patients with thyroid cancer.Reducing the Risk of Postpartum Depression Through Sleep Interventions
https://reachmd.com/programs/advances-in-womens-health/reducing-the-risk-of-postpartum-depression-through-sleep-interventions/32756/Establishing a sleep plan during the third trimester of pregnancy ensures that postpartum patients get sufficient blocks of sleep to support the well-being of the entire family. Here to share her insights on what this sleep plan can look like for new parents is Dr. Nicole Leistikow, Assistant ProfesThe Evolving gMG Treatment Landscape
https://reachmd.com/programs/neurofrontiers/the-evolving-gmg-treatment-landscape/30070/The newest findings on generalized myasthenia gravis treatment include FcRn inhibitors and B-cell targeting. Catch up now.Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
https://reachmd.com/programs/heart-matters/navigating-the-vascular-risks-of-cancer-therapy-balancing-cardiac-safety-and-tumor-control/37203/Cancer therapies can trigger both acute and chronic vascular effects, from treatment-induced hypertension to long-term atherosclerotic changes. Learn more as Dr. Jun-ichi Abe shares insights from his presentation at the 2025 American Heart Association Scientific Sessions. Dr. Abe is a Professor in tDiagnostic Approach for Prurigo Nodularis
https://reachmd.com/programs/dermatology-hub-neuroimmune-network/diagnostic-approach-for-prurigo-nodularis/37137/Practical Dermatology Editorial Board member Todd Schlesinger, MD, a board-certified dermatologist and Mohs surgeon with Epiphany Dermatology in Charleston, South Carolina, describes his diagnostic algorithm for prurigo nodularis.DESTINY-Breast04 Findings: T-DXd and Quality of Life in HER2-Low Metastatic Breast Cancer
https://reachmd.com/programs/frontlines-metastatic-breast-cancer/destiny-breast04-findings-t-dxd-and-quality-of-life-in-her2-low-metastatic-breast-cancer/36437/New insights from DESTINY-Breast04 highlight how trastuzumab deruxtecan (T-DXd) not only extends survival but also delays symptom deterioration in HER2-low metastatic breast cancer. In this AudioAbstract, Dr. Mimi Maeusli discusses key takeaways from the outcomes analysis and what they mean forInsights on Food Allergy Anxiety: Understanding and Supporting Patients
https://reachmd.com/programs/frontlines-food-allergies/insights-on-food-allergy-anxiety-understanding-and-supporting-patients/30038/Learn how food allergy anxiety disrupts a patient’s everyday life and what management strategies are recommended to alleviate its burden.Evolutionary Medicine: A New Frontier in Treating Chronic Gut Inflammation
https://reachmd.com/programs/gi-insights/evolutionary-medicine-a-new-frontier-in-treating-chronic-gut-inflammation/32329/Learn how evolution-based insights offer potential new therapeutic targets for chronic gut inflammation.Healthcare Cost Containment and Medical Liability Reform
https://reachmd.com/programs/heart-matters/healthcare-cost-containment-and-medical-liability-reform/5513/Defensive medicine and medical liability concerns create a symbiotic relationship that costs everyone in the medical system. Has healthcare reform legislation addressed the medical malpractice issue, and will it do enough to contain healthcare costs? Dr. Mark McClellan, director of the Engelberg CenHelping Adult Patients Find the Right Treatment for ADHD Symptoms
https://reachmd.com/programs/neurofrontiers/helping-adult-patients-find-the-right-treatment-for-adhd-symptoms/18149/Tune in to learn some best strategies for diagnosing and treating patients 25 years and older with ADHD.